JPRN-jRCT2080224088已完成2 期
A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without Chemotherapy in Patients with Advanced Pancreatic Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy
- •ECOG Performance status 0-1
- •Adequate organ functions
- •Measurable disease
排除标准
- •Suspected or known CNS metastasis
- •Participants with active, known, or suspected autoimmune disease
- •Uncontrolled or significant cardiovascular disease
- •Prior exposure to selected immune cell-modulating antibody regimens
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study of Cabiralizumab Administered in Combination with Nivolumab with and without Chemotherapy in Patients with Advanced Pancreatic Cancer.EUCTR2018-000339-28-GBBristol-Myers Squibb International Corporation200
进行中（未招募）
1 期
A Phase 2 Study of Cabiralizumab Administered in Combination with Nivolumab with and without Chemotherapy in Patients with Advanced Pancreatic Cancer.Advanced Pancreatic Cancer.MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2018-000339-28-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO200
进行中（未招募）
1 期
A Phase 2 Study of Cabiralizumab Administered in Combination with Nivolumab with and without Chemotherapy in Patients with Advanced Pancreatic Cancer.Advanced Pancreatic Cancer.MedDRA version: 20.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2018-000339-28-DKBristol-Myers Squibb International Corporation200
进行中（未招募）
1 期
A Phase 2 Study of Cabiralizumab Administered in Combination with Nivolumab with and without Chemotherapy in Patients with Advanced Pancreatic Cancer.Advanced Pancreatic Cancer.MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2018-000339-28-DEBristol-Myers Squibb International Corporation200
进行中（未招募）
1 期
A Phase 2 Study of Cabiralizumab Administered in Combination with Nivolumab with and without Chemotherapy in Patients with Advanced Pancreatic Cancer.Advanced Pancreatic Cancer.MedDRA version: 20.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2018-000339-28-ESBristol-Myers Squibb International Corporation200